Back to Search
Start Over
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries
- Source :
- Leukemia & lymphoma, Leukemia & lymphoma, Taylor & Francis, 2018, pp.1-8. 〈10.1080/10428194.2017.1421762〉
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- We examined real-world data on management of relapsed/refractory Hodgkin lymphoma (R/R HL) in five European countries and the consistency of these data with guideline recommendations. Retrospective clinical and epidemiologic data for 509 patients with R/R HL treated between January 2014 and March 2015 were collected at centers in France, Germany, Italy, Spain, and the United Kingdom. Mean age was 46.3 years; 73.3% were receiving second-line therapy for a first relapse during the reporting period. Most patients received ABVD as front-line chemotherapy, except in Germany where escalated BEACOPP was used more often. The proportion of patients receiving stem cell transplantation (SCT) was 44%; 85% of transplants occurred at first relapse. Brentuximab vedotin (BV) was usually administered after autologous SCT, and was initiated for 65% of patients following SCT failure. Our findings suggest that R/R HL management across these countries is broadly consistent with guideline recommendations and that BV is well-integrated into treatment pathways.
- Subjects :
- BEACOPP
Male
Cancer Research
autologous stem cell transplantation
Immunoconjugates
medicine.medical_treatment
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
0302 clinical medicine
Autologous stem-cell transplantation
Germany
Outcome Assessment, Health Care
Brentuximab vedotin
Child
ComputingMilieux_MISCELLANEOUS
Aged, 80 and over
Brentuximab Vedotin
Hematology
Middle Aged
Combined Modality Therapy
Hodgkin Disease
Europe
Oncology
Italy
030220 oncology & carcinogenesis
Child, Preschool
Female
France
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Transplantation, Autologous
03 medical and health sciences
Young Adult
Internal medicine
medicine
Refractory Hodgkin Lymphoma
Humans
Aged
Retrospective Studies
Chemotherapy
CD30
Hodgkin lymphoma
real-world data
business.industry
Guideline
United Kingdom
Transplantation
ABVD
Spain
business
030215 immunology
Stem Cell Transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 10428194 and 10292403
- Database :
- OpenAIRE
- Journal :
- Leukemia & lymphoma, Leukemia & lymphoma, Taylor & Francis, 2018, pp.1-8. 〈10.1080/10428194.2017.1421762〉
- Accession number :
- edsair.doi.dedup.....874c174a519509e89e64041b7d34cd51